GlobeNewsWire
01 Jun 2026, 05:15 UTC · 2h ago
Source · https://www.globenewswire.com/news-release/2026/06/01/3304002/0/en/Novartis-data-at-EULAR-2026-demonstrates-momentum-for-broad-immunology-portfolio-for-complex-high-unmet-need-diseases.html
Read source
Search tags
Story key points
3 claims · impact-rated
Novartis will present new data for its CAR-T therapy rap-cel and ianalumab at the EULAR Congress in June 2026. — Clinical data updates for pipeline assets in high-unmet-need areas typically drive short-term volatility and valuation adjustments based on efficacy results.
+0.40Novartis is showcasing new data for Cosentyx across several autoimmune diseases, including polymyalgia rheumatica and systemic lupus erythematosus. — Expanding indications for an existing blockbuster drug like Cosentyx increases the addressable market and long-term revenue potential.
+0.30The company has a total of 31 abstracts accepted for presentation at the EULAR Congress. — The volume of abstracts indicates a broad research footprint but is less market-moving than the actual results of the trials.
+0.10Ticker attribution
Continue reading
6 related stories
Model heads
The company is presenting new positive data across its immunology portfolio at a major medical congress, highlighting innovation and pipeline momentum.
No ticker relationship head found.
Impact vectors
4 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
GlobeNewsWire
1h ago
